瑞典系统性硬化症患者的生存情况:一项全国性基于人群的匹配队列研究
该研究基于瑞典全国登记数据,纳入2004至2015年诊断的1139例系统性硬化症(SSc)患者及5613名匹配对照,随访至2016年底。SSc患者5年生存率79.8%、10年生存率67.7%,均低于对照组的92.9%和84.8%(P<0.0001);死亡率42.1/1000人年 vs 15.8/1000人年,随访第一年末HR 3.7(95%CI 2.9, 4.7),随访结束时HR 2.0(95%CI 1.4, 2.8)。结论认为尽管诊断与疾病认识进步,SSc患者生存仍受严重影响。
要点
- SSc患者5年生存率79.8% vs 对照92.9%,10年生存率67.7% vs 84.8%(P<0.0001)。
- SSc死亡率42.1/1000人年 vs 对照15.8/1000人年,随访第一年末HR 3.7(95%CI 2.9, 4.7)。
- 随访结束时HR降至2.0(95%CI 1.4, 2.8),但生存仍显著受损。
核心结论
- 尽管过去几十年对疾病认识和诊断方法有所进步,2004至2015年诊断的瑞典SSc患者生存仍受到严重严重影响。
研究设计与样本
- 全国性基于人群的匹配队列研究,利用国家患者登记识别2004至2015年诊断的SSc患者,总人口登记按性别、出生年份和居住区域1:5匹配对照,随访至死亡、移居或2016年底。
- 共纳入1139例SSc患者和5613名匹配对照,SSc中位随访5.0年,对照中位随访6.0年。
主要发现
- 随访期间SSc患者死亡268例,对照死亡554例。
- SSc患者5年生存率79.8%、10年生存率67.7%,对照分别为92.9%和84.8%(P<0.0001)。
- SSc死亡率42.1/1000人年,对照15.8/1000人年;随访第一年末HR 3.7(95%CI 2.9, 4.7),随访结束时HR 2.0(95%CI 1.4, 2.8)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To conduct the first-ever nationwide, population-based cohort study investigating survival patterns of all patients with incident SSc in Sweden compared with matched individuals from the Swedish general population. METHODS: We used the National Patient Register to identify patients with incident SSc diagnosed between 2004 and 2015 and the Total Population Register to identify comparators (1:5), matched on sex, birth year and residential area. We followed them until death, emigration or the end of 2016. Follow-up of the general population comparators started the same date as their matched patients were included. We estimated all-cause survival using the Kaplan-Meier method, crude mortality rates and hazard ratios (HRs) using flexible parametric models. RESULTS: We identified 1139 incident patients with SSc and 5613 matched comparators. The median follow-up was 5.0 years in patients with SSc and 6.0 years for their comparators. During follow-up, 268 deaths occurred in patients with SSc and 554 in their comparators. The 5-year survival was 79.8% and the 10-year survival was 67.7% among patients with SSc vs 92.9% and 84.8%, respectively, for the comparators (P < 0.0001). The mortality rate in patients with SSc was 42.1 per 1000 person-years and 15.8 per 1000 person-years in their comparators, corresponding to an HR of 3.7 (95% CI 2.9, 4.7) at the end of the first year of follow-up and 2.0 (95% CI 1.4, 2.8) at the end of the follow-up period. CONCLUSION: Despite advances in understanding the disease and in diagnostic methods over the past decades, survival is still severely impacted in Swedish patients diagnosed with SSc between 2004 and 2015.
引用
- Bairkdar M, Chen EY, Dickman PW, et al. Survival in Swedish patients with systemic sclerosis: a nationwide population-based matched cohort study. Rheumatology (Oxford). 2023. PMID: 35984290. doi:10.1093/rheumatology/keac474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。